Sinovac applies for conditional marketing authorization of COVID-19 vaccine


BEIJING -- Beijing-based Sinovac Life Sciences Co., Ltd. on Wednesday filed an application with Chinese authorities for conditional marketing authorization of its anti-COVID-19 vaccine CoronaVac.
The application has been received by the National Medical Products Administration (NMPA), according to Sinovac Biotech Ltd., which has a majority stake in the vaccine producer.
The inactivated vaccine CoronaVac has made progress in phase three clinical trials overseas, showing a good level of safety after inoculation, according to a company statement.
Fourteen days after the inoculation of two doses of CoronaVac, the effectiveness of the vaccine in protecting against diseases caused by COVID-19 has met the relevant technical standards laid out by the World Health Organization and the requirements of the NMPA, the statement said.
- Hong Kong's economy grows steadily in Q1, hitting 5-quarter high
- Taiyuan officials draw lessons from April 30 explosion
- Xi's diplomacy injects certainty, stability into turbulent world
- Vibrant snapshots of China during Labor Day holiday
- Revised infectious disease law strengthens public health system
- Port in Macao sets new records on 1st day of May Day holiday